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Abstract: Although peptide therapeutics have been explored for decades, the successful delivery
of potent peptides in vitro and in vivo remains challenging due to the poor stability, low cell
permeability, and off-target effects. We developed a redox sensitive polymer-based nanocomplex
which can efficiently and stably deliver the peptide drug melittin for cancer therapy. The nanocomplex
selectively targets cancer cells through lactobionic acid mediated endocytosis and releases melittin
intracellularly upon the trigger of elevated redox potential. In vivo study proved that the targeted
nanocomplex shows excellent potency in inhibiting tumor growth in a xenograft colon cancer mouse
model. Thus, the polymer/melittin nanocomplexes will provide a new approach for melittin based
cancer therapy.
Keywords: nanocomplex; targeted delivery; melittin; redox sensitive; cancer
Key Contribution: A polymer/melittin nanocomplex was developed to selectively deliver melittin
into cancer cells and release intracellularly due to the endogenous high redox potential. This redox
sensitive polymer/melittin nanocomplex will provide a new approach for melittin based cancer therapy.
1. Introduction
Peptide-based drugs, which usually have less than 50 amino acids, hold a high potential for
treating various diseases. Furthermore, some peptide-based drugs have successfully entered the
market, such as cyclosporine, which is routinely used after organ transplantation to reduce the activity
of the immune system [1]. Some peptides can also be utilized as a cytosolic agent. One of the most
well-established peptides is luteinizing hormone-releasing hormone agonists for the combination
treatment of prostate cancer combined with radiation or chemotherapy [2,3]. The last decade has
witnessed the exponential growth of many peptide drugs entering clinical trials [4]. Specifically,
peptides hold many advantages for anticancer medications due to their high potency and a broad
range of targets. However, many hurdles, including vulnerability toward proteolytic digestion and
side effects due to off-targeting, have yet to be overcome [5–7]. For instance, the available cyclosporine
preparations showed a low bioavailability, high variation between patients, and the inability to obtain
both effective and safe doses [1].
Recently, melittin, a natural peptide from bee venom composed of 26 amino acids, has attracted a lot
of attention due to its anti-arthritis, anti-inflammatory, anticancer, and neuroprotective properties [8–13].
Melittin self-assembles into toroidal structures and induces the formation of pores on the cell membrane,
which ultimately results in cell death [14,15]. This unique cytolytic feature makes it impossible for cancer
cells to develop drug resistance. Due to the same reason, the non-specific cytolytic activity of melittin
could result in severe off-target effects, such as hemolysis (lysis of red blood cells), when administrated
intravenously. To make melittin druggable and safer, many approaches have been explored through
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environmental liable modification [16,17] or nanoencapsulation [18–20]. Previously, our group utilized
a dual-secured “nanobee” technology with the help of succinic anhydride-modified glycol chitosan
(SAMGC), and disulfide bonds successfully increased the therapeutic window of melittin to 10 µM [21].
The positively charged melittin forms nanocomplexes with a negatively charged SAMGC through the
electrostatic effect, while the disulfide bonds ensure that the encapsulated melittin can only be released
inside the cytosol, where it has elevated glutathione (GSH), to prevent the occurrence of hemolysis.
Our group recently developed a poly[(2-(pyridin-2-yldisulfanyl) ethyl acrylate)-co-[poly(ethylene
glycol)]] (PDAPEG) polymer [22–24], which can be easily modified by thiol-disulfide exchange reaction.
Thanks to this nature, a serial of zwitterionic polymers with different isoelectric points (IEPs) could be
produced by simply tuning the ratio of the introduced NH2 and COOH groups. Since the intracellular
environment usually contains a 1000-fold higher level of GSH than that in the extracellular milieus [25],
the high redox potential can be utilized to trigger the release of peptides by breaking the disulfide bonds.
To improve the specificity for cancer targeted delivery, various cancer cell-related receptors
have been explored. Among them, a β-D-galactose receptor, also known as ASGPR1, has been
extensively investigated. It was revealed that ASGPR1 receptor is expressed in multiple types of
cancer, including ovarian cancer, liver cancer, breast cancer, and colon cancer [26–28]. Therefore,
many ligands for ASGRP1 receptor have been developed, including lactobionic acid (LBA), for cancer
targeted therapy [29]. Colon cancer can develop acquired multidrug resistance during conventional
treatment [30] and has been validated for LBA targeting in our previous research.
Herein, we developed a redox responsive, ASGRP targeted polymer/melittin nanocomplex, for
the treatment of colon cancer. The negatively charged PDAPEG polymer derivative forms complex
melittin through electrostatic force. The nanocomplexes enter cancer cells through LBA mediated
endocytosis, subsequently dissociate due to the cleavage of disulfide bonds, and release melittin
intracellularly to kill cancer cells (Figure 1). Since there is no premature release of melittin before it
enters cancer cells, we believe this nanocomplex can translate targeted melittin therapy to a clinically
promising treatment with high efficiency and low side effects.
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Figure 1. Delivery pathway of targeted melittin nanocomplex for cancer therapy.
2. Results and Discussion
2.1. Design and Synthesis of Polymer LBA-PDAPEG
In our recent work, we prepared an environment-sensitive peptide delivery system, dual secured
nano-sting through the combination of a zwitterionic glycol chitosan and disulfide bond [21]. In that
design, melittin was successfully delivered into cytosol and released under the acidic pH and high
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redox environment. In this study, we aimed to deliver melittin through a redox sensitive polymer
PDAPEG, as shown in Figure 1.
The synthesis of LBA-PDAPEG is described in Figure 2. To introduce carboxylic acid groups and
amine groups into the PDA-PEG polymer, the pyridine ring was replaced completely by cysteamine
or 3-mercaptopropionic acid through thiol disulfide exchange reaction. The complete of the reaction
was confirmed by UV–vis and 1H-NMR. The signature peak of 2-pyridinethiol at 375 nm after
cleavage by tris(2-carboxyethyl)phosphine (TCEP) in the UV–vis spectrum disappeared after the thiol
disulfide exchange in Figure 3A. The disappeared protons in pyridine rings (8.46, 7.69, 7.11 ppm) in
the 1H-NMR spectrum, as shown in Figure 3B, support the conclusion. Successful conjugation of
3-mercaptopropionic acid was characterized by the –CH2CH2– protons (2.95, 2.74 ppm).
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Figure 2. The synthesis scheme of LBA-PDAPEG. i r . t i f - .
The composition of amine to carboxylic acid group determines the isoelectric point (IEP) of
polymer, which can be tuned by varying the feeding ratio of cysteamine to 3-mercaptopropionic acid.
The IEP points of polymers ranged from 9.5 to 5.0 when the cysteamine to 3-mercaptopropionic acid was
fed from 4/1 to 1/4 (Figure 4). The wide range of tunable surface charge of the polymers would allow for
the binding of peptides with different IEPs. The gentle electrostatic force between polymer and peptide
would prevent the potential denature of peptide if prepared with the traditional encapsulation method
accompanied with high intensive mechanical force or heat. In our study, we used a PDAPEG derivative
with a surface charge around −11 mV at the pH of 7.4 for nanocomplex fabrication. The targeting
moiety of LBA was conjugated to the amine group of through N-hydroxysuccinimide (NHS) and
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1-thyl-3-(3-(dimethylamino)propyl) carbodiimide (EDC) reaction. The conjugation was quantitatively
determined by the reduction of amine amount through a 2,4,6-trinitrobenzene sulfonic acid (TNBSA)
assay. The unmodified PDAPEG was determined to have 500 nmol pyridine rings per 1 mg polymer
with the co-incubation with 10 mM dithiothreitol (DTT). After the modification of both by cysteamine
and mercaptopropionic acid, the total amine amount was increased to 40.6 nmol per mg polymer.
After the conjugation of LBA, the available amine was decreased to 32.5 nmol per mg polymer, which
indicates a successful conjugation of LBA.
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2.2. Particle Characterization
Through electrostatic complexation, a negatively charged PDAPEG derivative formed with
complexed positively charged peptide elittin at physiology pH and further condensed it. After the
formation of complex, melittin was entrapped within the network of nano-structure and was protected
through the outlayer hydration of PEG. The nanocomplex showed a particle hydrodynamic size of
357 ± 30 nm (Figure 5). They were almost spherical according to transmittance electron microscopy.
In addition, the surface charge of nanocomplex dropped from −11.8 ± 0.64 to −4.24 ± 0.21 mV also
indicates the successful complexation with melittin. This proper size would allow for the passive
transportation of nanoparticles entering cancer cells through enhanced permeability and retention
effect [31].
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Figure 4. The surface charges of PDAPEG-NH2/PDAPEG-COOH at different amine to carboxylate
ratio responsive to environmental pH.
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Figure 5. Characterization of the nanocomplexes. Hydrodynamic size of nanocomplex in TBS buffer
measured by dynamic light scattering (A) and TEM image of nanocomplex (B). Scale bar in (B) is
200 nm.
2.3. High Redox Potential Environment Could Trigger the Release of Melittin
A unique feature of intercellular environment is its high reduction potential due to the elevated
GSH, which plays an important role in maintaining the reducing environment to prevent the excessive
oxidation stress from normal activities such as electron transfer from respiration or photosynthesis [32].
Our polymer LBA-PDAPEG would be almost neutral after exposing it to a high reduction environment
due to the lost functionalization of carboxylate group and amine group. Thus, the complex would be
dissociated quickly and would release melittin accordingly. To evaluate how the complex responds
to a high GSH environment, fluorescence resonance energy transfer (FRET) based nanocomplex was
prepared as described, using Cy3 as energy donor and Cy5 as energy receptor. Excited at 530 nm of
Cy3, the energy was transferred from PDAPEG-Cy3 (donor) to melittin-Cy5 (acceptor), which led to
an increased emission intensity at 670 nm. A reducing environment, such as 10 mM DTT, was able
to cleave carboxylate groups. The dissociation of neutral polymer and positive melittin led to a
decreased energy transfer, which decreased the fluorescence intensity at 660 nm as shown in Figure 6.
The fluorescence intensity was reduced by 20% after 50 min incubation with DTT, suggesting that the
nanocomplex integrity was partially compro ised by a i re cing environment.
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2.4. Hemolytic Assay
To evaluate the safety of the polymer/melittin nanocomplex, hemolysis assay was adopted.
Free melittin was able to lysis more than 80% of red blood cells (RBCs) at the concentration of 0.5 µM,
whereas the hemolytic activity of the polymer/melittin nanocomplex decreased with the increase of
polymer to melittin ratio (Figure 7A). No RBC lysis was observed for the nanocomplexes formed
at the polymer/melittin ratio of 30 at the melittin concentration of 5 µM, indicating the excellent
safety of the nanocomplexes. As expected, after the co-incubation with 10 mM GSH at 37 ◦C for 2 h,
the nanocomplex solution lysed 40% and 100% of RBCs at 2 µM and 5 µM, respectively (Figure 7B).
It is believed that the complex was dissociated upon the increased reducing environment and released
the free melittin to form pores on the surface of RBCs and lysis them.Toxins 2020, 12, x FOR PEER REVIEW 7 of 14 
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2.5. In vitro Cellular Uptake
It has been reported that LBA can bind to cancer cells membrane overexpressed D-galactose
receptors. To investigate the cellular uptake of LBA- ano omplexes, co focal microcopy was pplied.
With a short term of incubation with HCT 116 cells, LBA-modified nanocomplexes showed a significantly
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increased uptake compared with the non-targeted group, as evidenced by the brighter red fluorescent
(Figure 8). This data indicated that LBA could serve as a targeting moiety toward HCT 116 colon cells.
A similar LBA based targeting effect was also observed in the MCF-7 cells (data not shown).Toxins 2020, 12, x FOR PEER REVIEW 8 of 14 
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2.6. In vitro Anticancer Activities
The cytotoxicity of nanocomplex was investigated toward various cancer cells, including HCT
116 and MCF-7 cells, as shown in Figure 9. Compared with free melittin, non-targeted nanocomplex
showed a similar effect at low concentration but less effective at concentration higher than 1 µM in
killing cancer cells. Remarkably, the LBA-nanocomplex showed an enhanced cytotoxicity compared to
non-targeted nanocomplex and also significantly higher potency than free melittin at all concentrations.
For HCT 116 cells, the IC 50 for nanocomplex was 4.15 µM and the LBA-nanocomplex was 1 µM.
The targeting effect contributed a 76% decrease. Although melittin is more toxic toward MCF-7 cells,
which killed slightly less than 90% of cells at the concentration of 5 µM, LBA-nanocomplex could
almost eradicate all cancer cells at the same dose. Most melittin-loaded nanoparticles exhibit similar or
lower potency than free melittin in killing cancer cells [21,33]. Based on our findings and the reported
results from other research groups, we conclude that LBA-nanocomplex exhibited a better efficacy
toward various cancer cells than free melittin mainly due to its cancer-targeting effect [34].
Toxins 2020, 12, x FOR PEER REVIEW 9 of 14 
 
killing cancer cells. Remarkably, the LBA-nanocomplex showed an enhanced cytotoxicity compared 
to non-targeted nanocomplex and also significantly higher potency than free melittin at all 
concentrations. For HCT 116 cells, the IC 50 for nanocomplex was 4.15 µM and the LBA-nanocomplex 
was 1 µM. The targeting effect contributed a 76% decrease. Although melittin is more toxic toward 
MCF-7 cells, which killed slightly less than 90% of cells at the concentration of 5 µM, LBA-
nanocomplex could almost eradicate all cancer cells at the same dose. Most melittin-loaded 
nanoparticles exhibit similar or lower potency than free melittin in killing cancer cells [21,33]. Based 
on our findings and the reported results from other research groups, we conclude that LBA-
nanocomplex exhibited a better efficacy toward various cancer cells than free melittin mainly due to 
its cancer-targeting effect [34]. 
 
Figure 9. Cytotoxicity of melittin, control nanocomplex, and LBA-nanocomplex for various cancer 
cells. Cells were incubated with melittin nanocomplex and LBA-nanocomplex at melittin 
concentration from 0.1 to 10 µM for 24 h. Data represent mean ± SD, (A) HCT 116 cell; (B) MCF-7 cells; 
(C) Polymer cytotoxicity for HCT-116 and MCT-7 cells. * p < 0.05, ** p< 0.01, *** p < 0.001. 
2.7. In Vivo Experiment 
To assess the tumor growth inhibitory effect of the nanocomplex, the in vivo experiment was 
carried out in a xenograft HCT 116 colon tumor-bearing nude mouse model. Figure 10A revealed that 
polymer/melittin nanocomplexes remained active. Both the non-targeted and targeted nanocomplex 
can effectively inhibit the growth of tumors. After two weeks of treatment, the size of tumors in the 
nanocomplexes treated groups was around half of the tumor size in the control group. After the 
sacrifice of the animals, the tumors were isolated and weighed. Figure 10B indicated the tumor 
weight of LBA nanocomplex treated group was less than ¼ of that in the control group. 
Consequently, the LBA nanocomplex showed a significantly better tumor growth inhibitory effect 
than the control. 
A B
C
Figure 9. Cytotoxicity of melittin, control nanocomplex, and LBA-nanocomplex for various cancer
cells. Cells were incubated with melittin nanocomplex and LBA-nanocomplex at melittin concentration
from 0.1 to 10 µM for 24 h. Data represent mean ± SD, (A) HCT 116 cell; (B) MCF-7 cells; (C) Polymer
cytotoxicity for HCT-116 and MCT-7 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.
2.7. In Vivo Experiment
To assess the tumor growth inhibitory effect of the nanocomplex, the in vivo experiment was
carried out in a xenograft HCT 116 colon tumor-bearing nude mouse model. Figure 10A revealed that
polymer/melittin nanocomplexes remained active. Both the non-targeted and targeted nanocomplex
can effectively inhibit the growth of tumors. After two weeks of treatment, the size of tumors in the
nanocomplexes treated groups was around half of the tumor size in the control group. After the
sacrifice of the animals, the tumors were isolated and weighed. Figure 10B indicated the tumor weight
of LBA nanocomplex treated group was less than 14 of that in the control group. Consequently, the LBA
nanocomplex showed a significantly better tumor growth inhibitory effect than the control.
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3. Conclusions
In this study, we successfully developed a polymer/melittin based nanocomplex to evaluate its
safety and efficacy in can r therapy. It was revealed that the anocomplex can effectively deliver
melittin into cancer cells and release its contents responding to high red x otential nvironment while
protecting RBCs from the damag of free melittin. The LBA-nanocompl x is m r effective in killi g
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proved that the LBA-nan complex can ffectively kill cancer cells, thus resulting in significantly reduced
tumor progression in a xenograft colon cancer mouse model. This redox sensitive polymer/melitti
na ocomplexes will provide a new approach for melittin based cancer therapy.
4. Materials and Methods
4.1. Materials
Melittin was purchased from SERVA Electrophoresis GmbH (Heidelberg, Germany);
3-mercaptopropionic acid, aldrithiol-2, acryloyl chloride, poly(ethylene glycol)methacrylate
(Mn = 360 Da), cysteamine hydrochloride, hydrochloride acid, trimethylamine, 2-(N-morpholino)
ethanesulfonic acid (MES), 2,2-azobis(2-methylpropionitrile) (AIBN), lactobionic acid (LBA),
N-hydroxysuccinimide (NHS), and cysteamine hydrochloride were purchased from Sigma-Aldrich
(St. Louis, MO, USA). EDC (1-thyl-3-(3-(dimethylamino)propyl) carbodiimide) was purchased from
TCI (TCI America, Domorah, PA, USA); 2,4,6-trinitrobenzene sulfonic acid was purchased form Life
Technologies. Sodium dodecyl sulfate (SDS) was purchased from Bio-Rad Laboratories, Inc (Hercules,
CA). HCT 116 hu an colorectal cancer cells and MCF-7 breast cancer cells were obtained from
American Type Culture Collection (ATCC).
4.2. Preparation of Melittin Polymer
PDA (2(pyridine-2-yldisulfanyl)ethyl acrylate) was synthesized with using aldrithiol-2
and merc ptoethanol as described [23]. PDA was then copolymerized with poly (ethylene
glycol) methacrylate at 1:1 ratio through AIBN initiated free radical polymerization to obtain
poly[((2-(pyridin-2-yldisulfanyl)ethyl)acrylamide) co-[poly(ethylene glycol)]] (PDA-PEG).
In order to produce PDA-PEG polymer with different amounts of amine and carboxylate
groups, cysteamine and 3-mercaptopropionic acid were conjugated to PDA-PEG at different ratios
(amine/carboxylate, molar ratio) through the thiol-disulfide exchange reaction (Figure 2), and the
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resultant products were purified three times by precipitation in cold ether. Different feeding ratios
between cysteamine and 3-mercaptopropionic acid yield polymers with different isoelectric points (IEP).
LBA functionalization was carried out through EDC/NHS reaction. LBA was first activated with
EDC/NHS in 0.1M MES buffer at pH 6.0 for 30 min, and then polymer PDA-PEG with modification of
amine groups dissolved in PBS 7.4 at 20 mg/mL was added. The mixture was allowed to react overnight
at room temperature. Free LBA was removed by repeated dialysis using Spectra/Por® dialysis tube
(MWCO, 3.5 KDa) against dd H2O for 48 h. Purified polymer was freeze-dried and stored at −20 ◦C.
The pyridine concentration in the polymer was quantitatively determined by measuring the UV
absorbance at 375 nm after the cleavage by DTT. The concentration of pyridine was calculated based
on the extinction coefficient for pyridine-2-thione in DMSO at 375 nm (8080 M−1 cm−1). The molecular
weight of polymers was determined by GPC Viscotek GPCmax VE 2001 GPC solvent/sample
module equipped with Viscotek VE 3580 RI detector and 270 Dual Detector (Malvern Instruments,
Worcestershire, United Kingdom) using THF as mobile phase, and the structure composition was
determined by 1H-NMR. The success conjugation of 3-mercaptopropionic acid or cysteamine was
confirmed by 1H-NMR (Bruker Avance III HD 300, Billerica, MA, USA) and with a UV-vis spectrometer
(Beckman, DU650, Brea, CA, USA). The conjugation efficiency of LBA to PDA-PEG was quantified by
a 2,4,6-trinitrobenzene sulfonic acid (TNBSA) assay using cysteamine hydrochloride as standard.
4.3. FRET Measurement
The donor fluorescence dye Cy3-NHS was chemically conjugated with PDA-PEG, and the receptor
fluorescence dye Sulfo-Cy5-NHS was conjugated with melittin following our published method [29].
Cy3 labeled polymer and Cy5 labeled melittin were mixed to prepared nanocomplex. Samples were
loaded into Corning® 96 well black flat bottom plates and DTT was added to wells to cleave disulfide
bonds. Samples were excited at 500 nm with the cutting off at 530 nm. The entire fluorescence spectrum
(from 530 nm to 750 nm) of the complex treated prior to and after DTT was then recorded as a function
of the time with the help of a SpectraMax M5 Multi-Mode Microplate Reader (Molecular Devices,
San Jose, CA, USA).
4.4. Hemolysis Experiment
Rat whole blood was purchased from Bioreclamation (Hicksville, NY, USA). Red blood cells were
washed with 150 mM NaCl and centrifuged at 300 rcf for 2 min until the supernatant became clear.
The resulting red blood cells were suspended in PBS 7.4. Polymer complex or melittin was dispersed in
different buffers at a series of concentrations from 0.1 µM to 5 µM. To mimic the physiological condition,
nanocomplexes were dispersed in PBS 7.4 100 mM or PBS 5.0 100 mM. To mimic the intracellular
condition, nanocomplexes were dispersed in 150 mM PBS + 10 mM GSH and incubated at 37 ◦C for 2 h.
Melittin nanocomplex or melittin solution was incubated with above red blood cells for 1 h at 37 ◦C.
The release of hemoglobin was quantified by measuring the absorbance at 405 nm of the supernatant in
a microplate reader (ELX808, BioTek Instrument, Winooski, VT, USA) after centrifugation at 300 rcf. for
2 min. PBS and ddH2O treated RBCs were used as negative control and positive control, respectively.
The degree of hemolytic was calculated as the following formula: hemolysis % = (Abs(test) − Abs(PBS
negative control))/Abs(DI water positive control)) × 100%.
4.5. Cellular Uptake
HCT 116 colon cancer and MCF-7 breast cancer cells were cultured in Dulbecco’s modification
of Eagle’s medium (Corning, Glendale, AZ, USA) supplemented with 10% FBS and 1%
penicillin–streptomycin (Life Technology, Grand Island, NY, USA) at 37 ◦C in 5% humidified CO2
atmosphere. Cells were seeded in 35 mm Petri dishes with a density of 200,000 cells/petri dish and
allowed to grow overnight. Both non-targeting and targeting nano-complexes were applied to cells at
the Cy3 concentration of 2 µM for 3 h. Cells were washed three times with PBS and fixed with 4%
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formaldehyde, followed by staining with Hoechst 33,342 for 15 min. The cells were imaged with a
confocal laser scanning microscope (LSM 700, Zeiss, Oberkochen, Germany).
4.6. In Vitro Cytotoxicity
HCT 116 and MCF-7 cells were seeded in 96-well plates at the density of 20,000 cells/well and
incubated at 37 ◦C in 5% CO2 overnight. Melittin, non-targeted complex, or targeted complex were
diluted with a complete medium at desired concentrations ranging from 0.1 to 10 µM. After 24 h of
incubation, the media were replaced with 100 µL fresh media containing 1 mg/mL MTT reagent and
incubated for 4 h. The formed MTT crystal was dissolved with a stop solution, and the final optical
density of the medium was measured using a microplate reader (ELX808, BioTek Instrument, Inc.,
Winooski, VT, USA) at λ = 595 nm.
4.7. Tumor Growth Retardation Study
Female nude mice were purchased from the Jackson lab and randomly assigned into 3 groups
(3 mice/group). All animal experiments were conducted in accordance with NIH regulations and
approved by the Institutional Animal Care and Use Committee of the University of South Carolina
(Protocol No. 100851, approval date: 23 September 2015). Total 5 million HCT 116 cells suspended in
PBS were subcutaneously injected into mice. When the tumor volume reached about 30 mm3, the mice
were anesthetized with 3% of isoflurane and treated with LBA melittin nanoparticle at 2 mg/kg via
intratumoral injection. For control groups, the same amount of buffer used in preparing complex or
non-targeted nanoparticles was employed.
4.8. Statistics Analysis
Data was expressed as mean ± standard deviation and was analyzed using Microsoft Excel
and GraphPad Prism 6.0 (San Diego, CA, USA). Statistical analysis was performed using a one-way
Analysis of Variation (ANOVA) among treatment groups and the control group. A p value < 0.05 was
considered significant.
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